



Characterization ofAthsq1, an Atherosclerosis 
Modifier Locus on Mouse Chromosome 4: 
Identification of Cdkn2a as a modifier locus mediating 






Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 






















©  2011 
Chao-Ling Kuo 




Characterization of an Atherosclerosis Modifier Locus on Mouse Chromosome 4 
Chao-Ling Kuo 
Atherosclerosis, the primary cause of heart attack, stroke, and peripheral vascular disease, is 
genetically complex and the genes that confer cardiovascular risk remain largely unknown. 
Attempts to map common atherosclerosis susceptibility loci in humans have resulted in limited 
success. Mouse models provide an excellent tool for dissecting genetic complexity,and testing 
the role of candidate genes and pathways. While recent genome-wide association studies in 
humans have identified multiple genetic variants associated with atherosclerosis related traits- 
such as circulating lipid levels and hypertension- as well as myocardial infarction and stroke, 
few of the causal variants or underlying mechanisms are known. The work presented in this 
thesis identifies genetic loci contributing to atherosclerosis susceptibility in a murine model and, 
based on mechanistic data obtained in mouse, strongly suggests a mechanism underlying a 
coronary heart disease susceptibility locus on chromosome 9p21 identified by genome-wide 
association studies in humans.   
In this study we have used congenic mice that were previously constructed to isolate Athsq1, 
an atherosclerosis susceptibility locus identified in a cross between MOLF/Ei and C57BL/6J-
Ldlr-/-. Atherosclerosis studies performed in congenic mice carrying the MOLF-derived 
susceptibility allele from chromosome 4, in the C57BL/6J-Ldlr-/- background, confirmed the 
existence of the Athsq1 locus and BM-derived cells were shown to play an important role. 
Refined mapping of the Athsq1 locus identified at least two susceptibility loci within the interval. 
A proximal locus was narrowed to a region containing 8-21 genes, including the region of 
homology with the human coronary heart disease risk interval on chromosome 9p21. 
  
  
Interestingly, mRNA expression analyses in macrophages revealed markedly decreased 
Cdkn2a transcript expression in cells derived from congenic mice compared to the controls. 
Cdkn2a is a candidate locus associated with the 9p21 locus in humans. The potential role of 
bone marrow –derived Cdkn2a expression in atherogenesis was tested using a bone marrow 
transplantation approach with Cdkn2a-deficient donor cells. Mice receiving Cdkn2a+/-deficient 
bone marrow exhibited accelerated atherosclerosis, increased inflammatory monocyte subsets 
and increased monocyte/macrophage proliferation compared to the controls. This study 
provides a mechanistic link between decreased Cdkn2a expression, increased 
monocytes/macrophages proliferation with the expansion of an inflammatory monocyte subset 
and increased atherosclerosis. Together, these data illustrate the utilization of mouse models as 
tools to elucidate causal gene(s)/loci and potential pathophysiologic mechanisms underlying 
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A. Overview of atherosclerosis 
Prevalence and risk factors 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in both 
men and women worldwide.Although mortality rates of CVD have declined over the past 
four decades in the United States, about one-third of deaths in individuals over 35 years-
of - age are due to CVD complications (1, 2). It is estimated that approximately half of 
men and one-third of women at age 40 will manifest CVD complications 
(3).Atherosclerosis is the primary cause of CVD and strokewitha complex multifactorial 
etiology anda large genetic component underlying the disease.Despite numerous 
studies advancing our understanding of the etiology of atherosclerosis, the public 
disease burden remains high and maybe increasing(4). 
Data from epidemiological studies and randomized clinical trials led to the 
identification of risk factors that increase the susceptibility of CVD (5).“Risk factor” is 
defined as any measurable characteristic of an individual that predicts the individual’s 
probability of developing  a clinically manifest disease (Table 1-1)(6).Genetic factors, 
including elevated levels ofatherogenic lipoproteins,play a strong role in most formsof 
CVD.Obesity and diabetes, two common diseases with a large genetic component, also 
increase the risk of developing CVD.Elevated levels of C-reactive protein, a trace 
plasma protein secreted in response to inflammation, are associated with CVD, 
suggesting that genetic factors modulating inflammation may contribute to CVD risk. 
Environmental factors play an important role as well. Smoking, lack of exercise and fatty 
diet all increase the incidence of CVD(6, 7). Patients with periodontitis(infections of 
tooth-supporting tissues) have higher frequency of unstable angina, suggesting that 




additive. Thus, the complex etiologyof CVD results from the combination of an 
unhealthyenvironment, genetic susceptibility and gene-environment interactions. 
Table 1-1 Genetic and environmental risk factors affecting atherosclerosis and CVD 
Genetic factors 
Elevated levels of LDL/VLDL 
Decreased levels of HDL 
Elevated levels of Lipoprotein (a) 
Elevated levels of homocysteine 
Family history 
Diabetes and obesity 
Elevated levels of fibrinogen, plasminogen activator inhibitor type 1 and platelet reactivity 
platelet reactivity54. 
Gender (male) 







Adapted from (9, 10) 
 
Development and progression 
The normal artery consists of four major morphologically distinct concentric layers. 
The endothelial cell monolayer acts as a barrier between the blood and underlying tissue. 
The subendothelial space, orintima, is a very thin layer of extracellular connective tissue, 
mainly comprised ofproteoglycans and collagens. The peripheral side of it is surrounded 
by an internal elastic lamina. The middle layer, the media, consists mainly of smooth 
muscle cells that act to contract the vessel. The outer layer, adventitia, is composed of 





Numerous pathological and molecular studies have shed light on the morphological 
and cellular changes that occur during atherogenesis (reviewed in (9, 11)).The 
endothelium, connected by intercellular tight junctions, acts as a selectively permeable 
barrier between blood and tissues(12). It regulatesvascular tone, vascular 
remodeling,inflammation and thrombosis. Fluid shear stress is an important physical 
force acting on endothelial cells (ECs). Sites of low shear stress, high turbulent flow are 
the preferential vascular bed for the initiation of atherosclerosis (13).Cells in regions of 
arterial branching or curvature, where flow is disturbed, show increased permeability to 
macromolecules such as LDL and are preferential sites for lesion formation(12). 
Atherosclerosis studies in genetically altered mice showed that leukocyte adhesion 
molecules play a role in the initiation of atherosclerosis(14)(Figure 1-1). Monocyterolling 
on endothelial cells requires adhesion molecules of the selectin family. Apoe-/- mice 
deficient in P-selectin and E-selectin showed a reduction of atherosclerotic lesion 
formation(15). Ldlr-/- mice expressing a truncated form of vascular cell adhesion 
molecule-1 (VCAM-1) showed decreased early lesion formation (16). 
One of the key initiating events in atherosclerosis is LDL accumulation in the 
subendothelial matrix. LDL diffuses passively through endothelial cell junctions, and its 
retention in the vessel wall involves interactions between the LDL constituent 
apolipoprotein B (ApoB) and matrix proteoglycans(Figure 1-1). Other ApoB-containing 
lipoproteins, namely lipoprotein(a) and remnants, can also accumulate in the intima and 
promote atherosclerosis(17).The trapped LDL undergoes modification. One of the 




involved in such modification include12, 15-lipoxygenase (15-LO), inducible nitric oxide 
synthase (iNOS), myeloperoxidase (MPO), and various lipases(18).Modified LDL is 
taken up in an unregulated manner by scavenger receptors, SR-A and CD36, on 
macrophages to form lipid-engulfed “foam” cells(19, 20).Foam cells collect to form “fatty 
streaks”, the earliest lesion of the atherogenic process.  
High-density lipoprotein (HDL) exhibits multiple protective effects against 
atherosclerosis.HDL promotes reverse cholesterol transport via cholesterol efflux 
mechanismsinvolving ATP-binding cassette transporters(21, 22). In addition, HDL plays 
a protective role by inhibiting lipoprotein oxidation. The antioxidant properties of HDL are 
due in part to serum paraoxonase (PON1), an esterase carried on HDL that can degrade 
certain biologically active oxidized phospholipids(23).HDL also inhibits endothelial 
inflammation, promotes endothelial nitric oxide production, and inhibits platelet 
aggregation and coagulation(24).More recently, HDL has been shown to decrease 
leukocytosis by inhibiting the proliferation of hematopoietic stem and 
multipotentprogenitor cells and ultimately reverse accelerated atherosclerosis 
phenotypes(25). These data suggest that increasing circulating HDL levels may be a 







Figure 1-1 Initiation of atherosclerosis 
LDL is subjected to oxidative modifications in the subendothelial space. Minimally-
modified LDL (mmLDL) is oxidized extensively to form “oxidized LDL” (oxLDL) by 15-
lipoxygenase (15-LO) and inducible nitric oxide synthases(iNOS). Cell adhesion 
molecules expressed on endothelial cells recruitmonocytes. Adherent monocytes 
transmigratebetween endothelial cells and differentiate into macrophages promoted by 
M-CSF. oxLDL engulfed by macrophages via scavenger receptor CD36 or SR-A is 
subjected to esterification byacetyl-coenzyme A acetyltransferase(ACAT), leading to 
foam cell formation. ApoE secreted by macrophages facilitates cholesterol efflux to HDL 
or exportation of lipids via ABCA1 to HDL. Adapted from (11).   
 
Leukocyte recrutiment: 
The recruitment of monocytes and lymphocytes to the artery wall is triggered 
byoxLDL, which stimulatesECs to produce numerous proinflammatory molecules 
including adhesion molecules and growth factors, such as the macrophage colony-




mediated by VCAM-1 via interaction with integrin VLA-4 and adhesion molecules from 
the selectin family, E-selectin and P-selectin(26). Mice deficient in monocytechemotactic 
protein-1 (MCP-1) or its receptor, CCR2, have significantly reduced atherosclerotic 
lesions(27, 28), suggestingthat MCP-1/CCR2 interaction plays a role in monocyte 
recruitment in atherosclerosis.  
Lesion progression andthrombosis: 
As atherosclerosis progresses, accumulation of cholesterol ester, SMCmigration and 
proliferation,and SMC-derived extracellular matrix(ECM) depositionoccurs within plaques 
and leads to fibrous-fatty plaque formation. Cytokines and growth factors secreted by 
macrophages and T cells are important for SMC migration/ proliferation and ECM 
production. Activation of lesionalmacrophagesis characterized by expression of MHC 
class II molecules and inflammatory cytokine production, such as TNF-α, IL-6, and MCP-
1. Concomitantly, T cells expressboth Th1 (IFNγ) and Th2 cytokines (IL-4, IL-10)(Figure 
1-2) (29). As atherosclerotic lesions develop into advanced plaques, there can be 
ischemic symptoms as a result of progressive narrowing of the vessel lumen. On the 
other hand, acute cardiovascular events such as myocardial infarction (MI) and stroke 
could happen as a result of plaque rupture and thrombosis (30, 31). Plaque rupture 
usually occurs at the shoulder regions of plaquesexhibiting thin fibrous caps and large 
necrotic cores(30). The thickness of the fibrous cap reflects matrix production (secreted 
by SMCs) and degradation (by secreted metalloproteinases,MMPs).Plaque rupture 
exposes intimallipids and tissue factor to blood components, initiating a cascade of 
coagulation events, platelet adherence, and thrombosis (Figure 1-2). The 




protein in the initiation of the coagulation cascade. Neovascularization also affects the 
stability of atherosclerotic lesions, as it is prevalent in human advanced lesions.  
 
Figure 1-2 Lesion progression and thrombosis 
Interaction of macrophage foam cells and T cells creates a chronic inflammatory state. 
Cytokines produced by macrophages and lymphocytes are either pro-atherogenic (IFN-γ, 
CD40) or anti-atherogenic (IL-4, IL-10). Smooth muscle cells migrate from the medial 
wall to proliferate in the subendothelial space andsecrete extracellular matrix to form a 
fibrous cap.  As the plaque develops into a complex lesion, macrophages undergo 
apoptosis and necrosis to form a necrotic core. Matrix metalloproteinases secreted by 
macrophages lead to the thinning of the fibrous cap, resulting in a vulnerable plaque 
prone for plaque rupture. Plaque destabilization exposes blood components to tissue 
factor, initiating coagulation and the recruitment of platelets and thrombus formation. 
Adapted from (11).  
Monocytes and macrophages in atherosclerosis 
The role of macrophages is central to plaque development. Human monocytes were 
initially identified by high cell surface expression of CD14 (a component of the 
lipopolysaccharidereceptor) and CD16 (Fcγ receptor). Recently Cros et al.classified 
three distinct human monocyte subsets; CD14+CD16-accounting for 85% of blood 
monocytes, and CD14+CD16+ and CD14-CD16+ which comprise the remainder of 




Accumulating evidence suggests that monocytosisis an independent risk factor for 
CHD (33, 34). In addition, studies have revealed the importance of different monocyte 
subsets in association with CHD related complications. The predominant CD14+CD16- 
subset in patients with stable CHD has been correlated with risk factors and family 
history(35). CD14+CD16- cell counts correlate negatively with the serum concentrations 
of HDL and positively with levels of low density lipoprotein and lipoprotein(a) (36). 
However, after MI, it has been shown that CD14+CD16- monocyte counts exhibit an 
inverse correlation with left ventricular recovery(37).Interestingly, increased levels of the 
CD14+CD16+subset has been associated with preferential uptake of oxLDL(38), 
increased serum TNF-α levels (39)and increased cardiovascular events (39, 40).Further 
studies with careful classifications are required to define the relative role of monocyte 
subsets in atherogenesis. 
In mice, two subpopulations of circulating monocytes can be distinguished by the 
expression of Ly6C antigen(41). An“inflammatory” subset, Ly6Chi 
(CX3CR1
loCCR2+Ly6Chi), are released from bone marrow into the blood via CCR2 (42-
44) and preferentially recruited to inflamed tissues (41).A “resident”subset,Ly6Clo 
(CX3CR1
hiCCR2-Ly6Clo),have high expression of cell surface receptor CX3CR1 
(CX3CL1-receptor, mediates monocyte adhesion and survival (45)) and exhibits 
CX3CR1-dependent crawling on the endothelium of non-inflammed tissues(46).   
Monocyte subsets are functionally heterogeneous. During MI, Ly6Chi cells are 
mobilized from the spleen reservoirs (47)and scavenge necrotic debris in the damaged 
tissue to  produce TNF-α and proteolytic enzymes (48). In response to bacterial, viral or 




ward off infection (49, 50). During muscle injury, Ly6Chi expression decreases 
concomitant to increased expression of mature macrophage markers F4/80 and TGF-β 
(51). In contrast, Ly6Clo cells contribute to tissue healing in the infarcted myocardium 
rather than inflammation, promoting myofibroblast accumulation, angiogenesis, and 
deposition of collagen(48). They have also been shown to give rise to macrophage 
populations in the lung (52)and at the site of infection (peritoneum) (46). However, the 
exact function of Ly6Clo in atherogenesis remains to be determined. During 
atherosclerosis, Ly6Chimonocytes infiltrate into the lesions and differentiate into 
macrophages(53), this depends on CCR2, CCR5and CX3CR1(54). On the other hand, 
CCR2-Ly6Clomonocytes are partially dependent upon CCR5. This suggests that 
Ly6Chimonocytes could be a potential therapeutic target by antagonizing CX3CR1 in 
ameliorating CCR2+monocyte recruitment to plaques without impairing other CCR2-






Figure 1-3 Blood monocytes in atherosclerosis 
During atherosclerotic lesion development, inflammatory monocytes (Gr1+/Ly6Chi) are 
recruited into the intima and differentiate into macrophages. Patrolling monocytes (Gr1-
/Ly6Clo) patrol the endothelium scavenging lipid derivatives, dead and/or dying cells. 
Little is known about the influx and potential role of Gr1-/Ly6Cloin atherosclerosis 
progression. Adapted from (26). 
 
B. Genetics and atherosclerosis in humans 
Genetic factors play a significant role in atherosclerosis, with anestimated heritability 
of over 50%(55).Twin and familystudies have established that CHD aggregates in 
families(6). Family history of early onset CHD has long been considered a risk factor for 
disease(56). The most rigorous analysis of the inheritance of MI risk to date, the 
Framingham Offspring Study(57), found that individuals with at least one parent with 
premature CHD (defined as age of onset <55 years inmen,<65 years inwomen) 






to individuals with no suchfamily history.The investigators observed an odds ratio of 2.0 
and 1.7 in men and women,respectively, after adjustment for other traditional 
cardiovascular risk factors(57).Furthermore, sibling history of MI was observed to be a 
greater risk factor than parental history of early-onset CHD (58).These data established 
family history as a powerful risk predictor for CHD.  
Genes associated with a disease or trait can be studied in two ways. The first strategy, 
termed “forward genetics”, involves the testing of a hypothesis associated with a known 
candidate gene. This can be done by genetic modification of a known gene in rodent 
models, or testing for association of polymorphisms (variants that cause protein or 
functional alteration) in candidate genesin humans. The other method, sometimes 
termed, “reversegenetics”, involves linkage or association of a particular region of the 
genome with disease-without any prior knowledge about the underlying gene. This later 
approach involves genome-wide linkage and association studies(reviewed in (59)). 
Human Mendelian disorders 
Mendelian disorders are single-gene traits that are transmitted in an autosomal 
dominant, resessive or X-linked manner (60). Familial hypercholesterolemia (FH) is a 
classic example of a Mendelian disorder associated with CAD(6). This disease is due to 
mutations in the LDL receptor gene (LDLR). Individuals with homozygous FH have 
extremely high LDL cholesterol levels and often develop premature coronary artery 
disease. Loss-of-function mutations inLDLR were identified in fibroblasts derived from 
FH patients, and found to be transmitted within families in an autosomal dominant 
manner (61).Similarly, familial defective ApoB100 (FDB) results in hypercholesterolemia 
because the abnormal LDL binds poorly to LDL receptors(62). Mutations in the 




with autosomal dominant hypercholesterolemia (63). Tangier disease, resulting in 
extremely low HDL cholesterol levels, is an autosomal recessive disorder. In Tangiers, 
mutations in the ATP-binding cassette A1 gene (ABCA1) result in ineffective export of 
cholesterol from peripheral tissues to apolipoprotein A1, the major protein component of 
circulating HDL particles (64, 65). The identification of specific genes underlying 
Mendelian disorders have unraveled mechanisms for lipid metabolism and provided the 
opportunity to develop therapeutic targets for dyslipidemia, such as cholesterol-lowering 
drugs statins by promoting LDL catabolism. 
Linkage and association studies 
The success to new gene discovery starts with the establishment of genome-wide 
evidence for linkage or association in a single study, or consistent suggestive evidence 
in several independent studies(66). Linkage studies are performed by testing numerous 
genetic markers distributed throughout the genome to test for coinheritance of the alleles 
and the trait, and the output is given as a likelihood ratio statistic or a log of odds ratio 
(LOD) score (67). A LOD score >3 is considered significant evidence in humans and 
LOD scores of >2.8 and 4.3 are considered suggestive and significant evidence 
respectively for linkage in mice.  
Until recently, linkage analysiswas widely used in studies aimed at identifying new 
genes for CVD. Helgadottir et al.(68)performed linkage analysisusing Icelandic families 
(713 individuals) with MIand 1,068 microstatellite markers distributed throughout the 
genome. A linkage signal (LOD 2.86) was observed on chromosome (chr) 13. This 
interval was narrowed using an additional 120 microsatellite markers in 802 MI cases 
and 837 controls. A 4-SNP haplotype spanning the ALOX5AP gene (encoding 




MI(68).Another linkage study, involving a four-generation family with early-onset 
coronary disease transmitting in an autosomal dominant pattern, reported a linkage 
signal onchr 12p13(69). The linkage interval was narrowed to a 750-kb region harboring 
six genes.A missense mutation in LRP6 (LDL receptor-related protein 6) was found to 
segregate with family members having early onset CAD. This variant was not observed 
in 2000 controls.The mutation was further associated with high LDL, high triglycerides, 
hypertension, diabetes, and low bone density.Linkage analyses have been most 
successful in identifying rare causal variants with modest to large effects. However, such 
loci explain only a small percentage of the total population variance in risk for disease.  
Genome wide association studies (GWASs) and CVD 
The completion of the human genome sequence (70, 71), identification of millions of 
SNPs subsequently cataloged in public databases(72), and the initiation of the 
International Hap Map Project (73) have enabled us to further identify genes underlying 
common diseases. GWASs represent an unbiased genetic approach designed to detect 
common DNA variants (minor allele frequency >5%) associated with traits or diseases. 
These variants typically have modest to small effects on disease susceptibility. Using 
this approach, a dense set of SNPs are genotyped across the whole genome to search 
for genetic variants contributing to disease susceptibility or variation in levels of risk 
factors for disease-related heritable quantitative traits (74).  
Over the past few years, GWASs have identified numerous robust associations 
between SNPs on specific chromosomal loci and complex diseases such as type 2 
diabetes (75, 76), cancer (77, 78), Crohn’s disease (79, 80), rheumatoid arthritis (81, 82) 
and CHD(83, 84). Much success has been achieved for CHD-related traits including 




systolic blood pressure, diastolic blood pressure or hypertension have been identified 
(86, 87). Similarly, 95 loci associated with plasma lipid levels have beenidentified to date 
(88-90). A notable finding of these studies is that some of the same genes that cause 
Mendelian lipid disorders also underlie variation of lipid levels in the general population.  
The most highly replicated locus associated with CHD and MI identified by GWASs is 
a locus on chr 9p21 (91-94). This locus has been confirmed in multiple European groups 
(94-101), as well as other ethnic groups including Chinese (102), Japanese, Korean 
(101) and East Indian populations (103). The frequency of the risk allele is almost 50%, 
with a 20%-30% increased risk for CHD per copy (84). The high frequency of the risk 
allele confers a substantial impact at the population level. The locus is not associated 
with traditional cardiovascular risk factors such as blood pressure, cholesterol level, 
body mass index or smoking (94, 95), suggesting novel pathways influencing CHD 
and/or MI risk. Several studies have reported conflicting results about associations of 
9p21 with expression of nearby genes. Individuals carrying the risk allele have been 
shown to exhibit decreased expression of p16INK4a, p19ARF, and p15INK4b -inhibitors of 
cellular proliferation encoded by the nearby CDKN2A/B locus – as well as proximal 
transcripts of a non-coding mRNA ANRIL, in some studies (104-106) but not others (107, 
108). The inconsistency of these data may be due to relatively small sample sizes or 
tissue specific regulation of CDKN2A, CDKN2B and MTAP genes.   
Studies have shown that risk variants of 9p21 do not affect early CHD markers, such 
as carotid intima-media thickness and brachial flow-mediateddilatation (109). On the 
other hand, Horne et al. found no association of 9p21 with either the severity or extent of 




role at an early stage of CHD (110). It remains to be determined at which stage this 
locus comes into action.  
There are several findings of chr 9p21 that show the genetic complexity of a human 
disease locus. Firstly, the locus underscores the importance of non-traditional risk 
factors in determining disease susceptibility. Only 2 out of 8 chromosomal regions 
affecting MI or CHD (in replicated studies) (84, 111-113) are associated with traditional 
risk factors, thus suggesting novel mechanisms underlying disease. A robust association 
was found with abdominal aortic aneurysm and intracranial aneurysm (98, 114), 
suggesting that the underlying gene affects local vessel wall integrity. Secondly, two loci 
that are associated with type 2 diabetes (T2D) map to a similar region of chr 9p21 (82). 
However, the associated SNPs flank the CHD risk locus (with no overlap), implicating 
that the causal genes and/or regulatory loci for CHD and T2D are distinct. Thirdly, the 
associated SNPs map to a region with no known protein coding genes (Figure 1-4). The 
linkage disequilibrium (LD) block, ~58 Kb, lies more than 100 Kb away from the nearest 
protein coding genes, CDKN2A (encoding p16INK4a, p14ARF), CDKN2B (p15INK4b) and the 
MTAP gene (methylthiosadenosine phosphorylase). This suggests the possibility that 
the causative variants are non-coding RNAs or regulatory elements affecting expression 
of one or more flanking genes. Despite these discoveries, the causative the link between 





Figure 1-4 Genomic organization of the CDKN2A/B locus near the 9p21 CHD locus. 
(A) The exon-intron structure of annotated genes is shown in different colors for 
distinction. p16INKA andp14ARF share exons 2 and 3 but have different exon1, resulting in 
two different reading frames encoding two distinct proteins. The ANRIL gene overlaps 
the two exons of p15INK4b and is transcribed in opposite direction from the p15INK4b, 
p16INK4a, p14ARF (mouse: p19ARF) genecluster.  
(B) The linkage disequilibrium (LD) blocks on chr 9p21.3. Regions of LD are shaded on 
a continuous scale, with red and white the strongest and least association respectively. 
Haplotype blocks are framed by triangles.Figure adapted and modified from (115). 
 
C. Mouse genetics and atherosclerosis 
Atherosclerotic mouse models 
Two strains of genetically modified mice have been used for studying atherosclerosis: 
Apoe-/- and Ldlr-/-. Apoe-/- mice lack apolipoprotein E, a key component in cholesterol 
metabolism.Apoe-/- mice develop spontaneous hypercholesterolemia and atherosclerotic 





Low-density lipoprotein receptor (Ldlr)-deficient mice develop atherosclerosis only when 
fed a high-cholesterol diet (67). Crossbreeding of these mice with animals carrying 
deletion/overexpression constructs or tissue-specific promoters allows for testing the role 
of candidate genes and tissues in atherosclerosis development. Moreover, the use of 
bone marrow (BM) transplantation offers insights to the role of BM or non-BM derived 
cells in the pathogenesis of the disease. 
Complex trait and disease locus mapping strategies 
The efficiency of mapping loci for complex traits in the mouse ultimately depends on 
good genetic mapping resolution. Interval-specific congenica provide one approach to 
QTL fine mapping in rodents. These mice are created by repeated backcrossing of mice 
carrying a specific disease susceptibility interval from a donor strain into a recipient 
background strain. Using marker-assisted selection, a particular genomic region of 
interest can be selectively introgressed from the donor strain into the recipient 
strain(117). Subsequent intercrossing is then performed to generate segment 
homozygotes. Isolating the region of interest in a uniform genetic background enables 
the standardization of genetic background effects and allows characterization of the 
phenotype in multiple genetically identical individuals (reviewed in (118-120)). Thus, 
interval-specific congenics provide a valuable tool to identify genes underlying complex 
traits/diseases of interest. 
There are several practical considerations when narrowing the susceptible interval 
and identifyingthe underlying genes. Regions that are identical by descent between two 
parental strains are highly unlikely to contain causal genetic variants underlying QTLs 
and can be excluded as candidate regions. Wild-derived mouse strains provide great 




degree of polymorphism complicates the distinguishing of causal and non-causal SNPs 
(118).  
Comparative mapping of mouse and human atherosclerosis-related QTLsreveals that 
many mouse QTLs found in both Apoe-/- and Ldlr-/-crosses are concordant with the 
mapped locations of human QTLs, and vice versa (121). Comparative mapping can 
facilitate the identification of genes underlying QTLs by excluding non-concordant 
regions of the mapped intervals. This is based on the assumption that orthologous 
genes underlie QTLs in both species, thus narrowing down the regions of interest. For 
atherosclerosis, 13 of 21 (62%) of mouse QTLs are concordant with human QTLs, and 
17 of 27 (63%) of human QTLs are concordant with mouse QTLs (122). This suggests 
that more than half of the disease loci underlying atherosclerosis QTLs are conserved 
between mouse and human. Using this approach may facilitate the pinpointing of loci 
/genes that are relevant to human diseases.  
Genes identified from QTL studies 
The identification of causal genes underlying atherosclerosis QTLs in model 
organisms has been modestly successful. Two examples for mouse atherosclerosis 
QTLs are 1) arachidonate 5-lipoxygenase (Alox5) underlying QTL Artles (for arterial 
lesions) on chr 6; and 2) tumor necrosis factor, superfamily 4 (Tnfsf4, a.k.a. Ox40l) for 
QTL Ath1 (for atherosclerosis susceptibility 1) on chr 1. 5-LO is the rate-limiting enzyme 
in leukotriene synthesis and is expressed primarily in leukocytes, including monocytes 
and macrophages. Leukotrienes are potent pro-inflammatory lipid mediators and it has 
been suggested that 5-LO could play a role in atherosclerosis by regulating these 
pathways. The original linkage peak for Artles was found in an F2 population derived 




changes were associated with reduced 5-LO expression in the congenic C57BL/6J mice 
carrying the CAST atherosclerosis Alox5 allele (124). The creation of reciprocal 
subcongenic lines showed that two other loci within the same QTL, named Ath37 and 
Ath38, play significant roles in the effect of this QTL (125). Genetic linkage and 
association studies in Icelandic families subsequently revealed genetic variants in 
ALOX5AP that confer risk for MI and stroke, likely through increased production of 
leukotrienes in neutrophils (68). The associated SNPs in the ALOX5AP were further 
confirmed in Scottish, Japanese and European descent in the US (68, 126-128). This 
provides an example of identifying genes underlying human disease using mouse QTL 
studies. 
Another example is the identification of Tnfsf4 by Wang et al. (129). The Ath1 locus 
was originally mapped to a 0.66 cM interval on chr 1 in a cross between C57BL/6J and 
C3H/ HeJ (130, 131). Tnfsf4, coding for Ox40 ligand (Ox40L), is expressed in the aorta 
and the level of its expression was significantly higher in the atherosclerosis susceptible 
C57BL/6J strain than in the resistant C3H/ HeJ strain. The Ox40L-Ox40 pathway is 
known to control lymphocyte proliferation and survival. Mice overexpressingTnfsf4 
manifest more atherosclerosis than wild- type mice. Deficiency in Tnfsf4 expression, or 
inhibition of the Ox40L-Ox40 pathway, protects from atherosclerosis (132). In addition, 
human association studies showed that polymorphisms in TNFSF4 were more frequent 
in individuals with MI (129) and stroke (133) than unaffected controls. These data 
support a role forTnfsf4 in determining disease susceptibility in mouse and human. 





More recently, integrating genetic and gene expression data has been successful in 
mapping genes underlying complex traits. Transcripts influenced by loci nearby to the 
structural genes are referred to as cis-acting QTLs; others influenced by loci mapping to 
a completely different genomic location are referred to as trans-acting QTLs. When cis-
QTLs co-localize with QTLs for a clinical trait, they can facilitate the identification of the 
causal genes. Successful examples include identifying candidate genes underlying 
behavioral phenotypes using brain tissues from recombinant inbred lines (134). Another 
example includes the lipoxygenase gene, Alox15, that was found to be an important 
regulator of bone mass using a differential gene expression approach comparing 
congenic vs non-congenic mice. The role of Alox5 was further proven using knockout 
mice and pharmacological inhibitors targeting the encoded enzyme and showing 
improve Subsequent intercrossing is then performed to generate segment homozygotes. 
Isolating the region of interest in a uniform genetic background enables d bone density 
and strength (135). These studies have demonstrated the great potential for systems 
biology approaches, allowing the identification of networks of coregulated genes and 
pathways (136, 137). 
The utility of genes/loci identified by human GWASs requires the elucidation of 
functional mechanisms underlying disease. Recently, the CELSR2-PSRC1-SORT1 
locus was identified by GWAS to be associated with LDL levels and MI. Using 
genetically altered mice, it was demonstrated that a non-coding polymorphism creates a 
transcription binding site that alters Sort1 expression, thus altering plasma LDL and 
VLDL by modulating hepatic VLDL secretion (138, 139). Therefore, genetically-altered 
mouse models provide great tools to understand the functional mechanisms of DNA 





Table 1-2 Examples of candidate genes identified for complex traits in genetic studies 
using rodent models 
Gene 
symbol 




Alox15  Arachidonate12/15 Abnormal bone 
mass 
4% Expression differences, 





Rgs2  Regulator of G-
protein signaling 2 
Fear-related 
behavior 
5% Outbred mice, QTL–
knockout interaction 
(140) 





5% Congenics, sequence 
variants 
(141) 







8% Expression differences, 
loss-of-function mutation 
(143) 
Ace2  Angiotensin 1 Abnormal blood 
pressure   
12% Knockout phenotype (144) 
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J, member 10 
Susceptibility to 
seizure 









receptor type, J 
polypeptide 
Susceptibility to 








Tas1r3 Taste receptor, 





sequence variants  
(150) 




precursor A hypertrophy increase gene 
expression 
Cd36 Fatty acid 
translocase 
Abnormal fatty acid 
metabolism 





Pla2g2a  Phospholipase A2, 
group IIA(platelets, 
synovial fluid) 
Modifier of tumors 
in intestinal cancer 
50% Frameshift loss of 







Modifier of hearing 
loss 





Adapted from (120) 
D. Aim of the thesis 
The aim of this thesis is to identify an atherosclerosis susceptibility gene underlying 
the Athsq1 locus on mouse chr 4. Chapter two focuses on fine mapping of the chr 4 
locus and identification of the cell types that are important determinants of the disease 
phenotype. In chapter three, gene expression analyses, functional analyses, and a 
gene-targeted mouse model are used to implicate the Cdkn2a locus (encoding p16INK4a 










Objective: Cardiovascular disease is complex, involving both genetic and environmental 
factors. Much effort has focused on identifying underlying genetic factors but with 
modest success. A mouse genetics approach provides tools to dissect genetic 
complexity and provide uniform models for mechanistic studies.  
Methods and results: Atherosclerosis susceptibility QTL1 (Athsq1) was previously 
identified on chromosome (chr) 4 in a cross between MOLF/Ei and C57BL/6J-Ldlr -/-. 
Congenic mice carrying the MOLF-derived susceptibility allele in the C57BL/6J-Ldlr -/-
genetic background confirmed the existence of the Athsq1 locus and revealed an 
association with increased accumulation of versican, presumably a proatherogenic 
matrix component abundant in human lesions. Here we provide refined mapping of the 
Athsq1 locus by creating a series of subcongenic strains. A distal locus in the Athsq1 
interval shows proatherogenic activity after 6-wk western type diet (WTD) feeding, while 
an interval located near the proximal end of the Athsq1 locus is capable of conferring 
atherosclerosis later during the development of the plaque (9-wk WTD feeding). The 
proximal interval was further narrowed to a genomic region containing 8-21 genes, 
including the region of homology with a human CHD risk interval on chr 9p21. Bone 
marrow (BM) transplantation studies were performed to identify cell types that are 
responsible for the atherosclerosis phenotype. B6-Ldlr-/- mice receiving BM derived from 
the Athsq1 congenic exhibited increased atherosclerotic lesion area and versican 
accumulation compared to the controls. A reciprocal BM transplantation study confirmed 
that smooth muscle cells (SMCs) and endothelial cells (ECs) are not involved in the 




the accelerated atherosclerotic phenotype is mediated by BM-derived cells but not 
resident cells of the vascular wall. 
Conclusions: This study confirms that there are at least two loci in the MOLF-derived 
Athsq1 locus that have proatherogenic activity with the smallest locus containing 8-21 
genes. In addition, we found evidence that BM-derived cells are causative for the 





CHD is highly prevalent in the population and remains an important public health 
challenge. Atherosclerosis is the main cause of CHD and is a complex disease resulting 
from genetic, environmental and gene-environment interactions. Attempts to identify the 
genetic components have been hampered by clinical and genetic heterogeneity, 
polygenic inheritance and environmental factors. Intense effort has been made to dissect 
the genetic component of atherosclerosis using traditional genetic approaches but with 
modest success (155). Animal models can facilitate the discovery of genetic factors and 
molecular pathways underlying human disease.  
Quantitative trait loci (QTLs) were initially mapped in mouse using recombinant 
inbred lines (32, 130, 156).  Later studies reported the use of congenic strains to identify 
QTLs (40, 123, 157-159). To date, more than thirty different mouse atherosclerosis loci 
have been identified (121). However, very few of the underlying genes have been 
identified and tested for a role in human disease. Apoa2 was the first gene identified by 
mouse genetic mapping (160, 161), with increased levels of apoA-II associated with 
metabolic disorders in humans (59). Similarly, Alox5 and Tnfsf4 were identified by 
mouse genetic mapping and polymorphisms in these genes have been found to be 
associated with MI and stroke in humans (68, 124, 129). Thus, mouse genetic mapping 
provides a great tool to identify underlying genes for atherosclerosis-related traits and 
ultimately discover mechanisms for human disease.  
We previously reported the localization of atherosclerosis susceptibility QTL 1, 
Athsq1, to chr 4 using a cross between strains MOLF/Ei and C57BL/6J-Ldlr -/-(157). The 
Athsq1 locus was confirmed with the creation of congenic strains (162). Congenic mice 
carrying a 54-Mb atherosclerosis susceptibility locus derived from the MOLF strain was 




exhibited up to 4.5-fold greater lesion area compared to noncongenic littermates 
(p<0.0001). This locus affects lesion susceptibility in a gene dosage dependent manner 
and acts independently of plasma lipid levels. Lesions from the congenic mice exhibited 
more advanced plaque characteristics including thick fibrous caps and greater necrotic 
core areas compared to controls. These mice also exhibited prominent accumulation of 
a proatherogenic matrix protein, versican, located at the intima-media interface beneath 
plaques. However, the large interval (54 Mb) contained numerous genes (~650 genes) 
making candidate gene analysis impossible at this point.  
Here, we report refined mapping of the Athsq1 locus to narrow the list of candidate 
causal genes by generating a series of subcogenic strains. Using different durations of 
WTD feeding, we identified at least two loci in the Athsq1 interval. One of these loci was 
narrowed down to a 5.4-9 Mb interval that contains the region of homology to a human 
CHD locus on 9p21 (91-94). BM transplantation studies revealed that the accelerated 
atherosclerosis and versican accumulation in the congenics are mediatedby BM–derived 
cells, not SMCs or ECs. 
 
 
Material and Methods 
Mice. MOLF/Ei (MOLF) and B6.129S7-Ldlrtm1Her (B6-Ldlr–/–)mice were purchased from 
The Jackson Laboratory (Bar Harbor,ME). B6.MOLF-Athsq1congenic mice were 
generated by introgressionof a 54 Mb MOLF donor interval into the B6-Ldlr–/– 
background, followed by intercrossing to produce homozygotes as described (162). 
Subcongenic mice (17, 11, 4Mb and Sub-B and -C strains) were derived from the 54 Mb 




microsatellite markers spanning the 54-Mb interval inherited from the MOLF parental 
strain. Mice carrying similar (ie. closely-located) breakpoints were intercrossed at N13-
N17 generations. A 51 Mb congenic strain carrying a nearby breakpoint relative to the 54 
Mb interval was also used for BM transplantation studies and versican staining. An 
atherosclerosis study was performed on 51 and 54 Mb congenics, which were derived 
from the N6 and N14 generation respectively. There is a clear lesion susceptibility 
phenotype present in both the 51- and 54-Mb strains (Figure 2-1) (the difference may be 
due to experiment-experiment variation). These data suggest that the lesion phenotype 
was still present in a more uniform (N14) background and not dependent on the 
presence of other donor regions present at the N6 generation. Subcongenic mice (males 
and females) were fed Western-type diet (WTD) (TD88137; Harlan Teklad) for 6- or 9-
weeks before sacrifice as indicated. All procedures were in accordance with Institutional 
guidelines.  
 





Atherosclerotic lesion area in (A) 51 Mb congenic mice (220 577 ± 153 238 µm2/section) 
vs the controls (52 526 ± 17 512 µm2/section) after a 6wk WTD compared to (B) 54 Mb 
congenic mice (22 3726 ± 38 938 µm2/section ) vs the controls (111 543 ± 69 664 
µm2/section) after 7 wk WTD.  These data suggest that the lesion phenotype was still 
present in a more uniform (N14) background and not dependent on the presence of 
other donor regions present at the N6 generation. Shown is mean ± SD.  
 
DNA Extraction and LdlrGenotyping. DNA was extracted from tail tips by an alkaline 
lysis protocol (164). Briefly, the tail tips were incubated in 50mM NaOH for 1hr at 95°C, 
vortexed and neutralized in 1 M Tris (pH 8). Cellular debris was pelleted by 
centrifugation and the supernatant was used for genotyping. Ldlr alleles were typed by 
polymerase chain reaction (PCR) with the primer information obtained from 
http://jaxmice.jax.org/protocolsdb/f?p=116:2:2955415530757048::NO:2:P2_MASTER_P
ROTOCOL_ID,P2_JRS_CODE:6048,007068 (157,162).Custom-made oligonucleotides 
were synthesized commercially (Invitrogen). Microsatellite markers were typed by PCR 
using the following protocol: 30 seconds denaturing at 95 °C, 30 seconds annealing at 
60 °C, 2 minutes extension at 72 °C for a total of 35 cycles, and one final extension at 72 
°C for 10 minutes.  
Atherosclerotic Lesion Measurements. Serial sections were prepared from the aortic 
root as described (157,162). Anesthetized mice were killed by cervical dislocation. 
Mouse hearts were perfused using 10 ml of PBS (Invitrogen), and the aortic roots were 
dissected and fixed in 10% formalin (Fisher). 6-μm sections from the proximal aortas 
were serially paraffin-sectioned and stained with hematoxylin and eosin (H&E) (Sigma). 
Lesion areas were quantified by morphometric analysis using every tenth section, for a 
total of six sections per mouse. Morphometric analysis was performed by outlining lesion 




aortic lesion area was obtained by averaging lesion areas from six sections from the 
same mouse.  
Immunohistochemistry. Aortic tissues of 6-μm paraffin-embedded sections mounted 
on Super Frost slides were deparaffinized, rehydrated, and stained for versican using a 
rabbit polyclonal antibody against the β-gag domain (Chemicon International) and 
detected by an indirect avidin–biotin–peroxidase method. Briefly, sections were 
sequentially incubated and washed in phosphate-buffered saline (PBS). A polyclonal 
antibody specific for versican was diluted to 6-8 µg/ml in PBS, followed by hybridization 
with biotinylatedgoat anti-rabbit IgG and avidin-biotin-peroxidase complex. Sections 
stained without primary antibody were used as negative controls.  
BM Transplantation. BM transplantation was performed as previously described (165). 
Recipient mice were given acidified water (pH 4.5) containing 100 mg/liter neomycin 
(Sigma) and 10 mg/liter polymyxin B sulfate (Sigma) one week before and two weeks 
after BM transplantation. Eight-week-old male or female B6- Ldlr−/− mice were lethally 
irradiated with 1000 rads (10 Gy) from a cesium gamma source. BM was collected from 
femurs and tibias of donors, by flushing with sterile RPMI 1640 media containing 2% 
FBS, 5 U/ml heparin, 50 U/ml penicillin, and 50 μg/ml streptomycin. Each recipient 
mouse was injected with 4–5 × 106 BM cells through the tail vein. Reconstitution of the 
BM with donor cells was checked at 6 weeks postinjection using microsatellite marker 
D4Mit185, located within the 17-Mb donor interval. Mice were then fed WTD for 11 
weeks, euthanized, and the aortic roots dissected and sectioned as above.  
In the first BM transplantation study, irradiated recipient B6-Ldlr–/– mice were injected 




recipient B6-Ldlr–/– or 17-Mb congenic mice were each injected with BM donor cells from 
B6-Ldlr–/– mice.  
Statistical Analysis. ANOVA and t-test were performed with or without square root 
orlog transformation, as indicated, using STATVIEW 5.0 (Abacus Concepts,Inc). Both 
males and females were included in the lesion analyses using genotype and sex as 
factors in the ANOVA. The threshold for significance was set at p = 0.05. Data shown 
are mean ± SD. 
Results 
Fine mapping of the Athsq1 locus reveals at least two atherosclerosis 
susceptibility loci within the 54 Mb interval. In order to refine the localization of the 
susceptibility gene(s) residing in the Athsq1 locus, subcongenic strains were created. 
Athsq1 full congenics were backcrossed to B6-Ldlr-/- mice. Chromosomal recombinations 
were identified using microsatellite markers polymorphic between MOLF and B6. 
Heterozygotes carrying similar (i.e. closely located) breakpoints were intercrossed to 
produce homozygotes. In total, six homozygous subcongenic strains were created 
(Figure 2-2,A). Strains carrying a 17-, 11- or 4-Mb proximal region of the MOLF-derived 
interval, as well as a strain carrying just the distal end of the 17-Mb interval (Sub-C) were 
identified. In addition, a Sub-B strain was identified carrying a distal end of the 54-Mb full 
interval (Figure 2-2,A). 
Following 6-wk WTD feeding, mean lesion area of 17-Mb congenic mice did not 
differ significantly compared to the control strain (b/b) (Figure 2-2, B). Consistent with 
this observation, mice carrying the 11- or 4-Mb and Sub-C intervals, which cover the 




lesion area compared to the b/b controls. However, the Sub-B congenic strain, which 
carries the distal end of the 54 Mb interval, exhibited significantly larger mean lesion are, 
a than the controls, indicating the existence of one or more susceptible alleles (Figure 
2-2B). Thus, at the 6-wk feeding timepoint, a distal locus within the 54-Mb interval 
confers susceptibility for atherosclerosis.  
Analysis of atherosclerotic lesion development was then determined in a subset of 
congenic mice following 9-wk WTD feeding. Mice carrying the 17- or 11-Mb subinterval, 
but not the 4-Mb interval, exhibited approximately 2-fold greater mean lesion area than 
non-congenic controls (p<0.0001) (Figure 2-2, C). These data indicate that there is a 
locus at the proximal end of the 54 Mb interval, excluding the 4-Mb region, that is 
detectable only after a longer (9-wk vs. 6-wk) WTD feeding period.  
Together, these data suggest that there are at least two different loci contributing to 
atherosclerosis susceptibility in the Athsq 1 congenic mouse, possibly acting at different 
stages of atherogenesis. 
To determine whether versican accumulation was associated with the proximal 
locus, immunostaining was performed in lesions derived from 17-Mb congenic or non-
congenic control mice. Using an antibody directed against the β-gag domain of versican, 
17-Mb congenic mice showed a prominent accumulation of versican compared to 
controls (Figure 2-2, D). These data suggest that versican plays a role in the 





Figure 2-2 Refined mapping of the Athsq1 interval reveals two distinct loci detectable 
after different periods of WTD feeding. 
(A) Physical map used for the construction of subcongenic strains on mouse chr 4. A 
series of subcongenic strains derived from the 54-Mb full congenics was created. The 
extent of MOLF donor intervals (white boxes) introgressed into the B6-Ldlr-/- background 
(black boxes) is indicated along the top in Mb; b/b, homozygosity for B6 alleles; m/m, 
homozygosity for MOLF alleles. (B) Mean lesion areas for each subcongenic strain after 
a 6-wk WTD feeding period. The increased atherosclerotic lesion area observed in the 
Sub-B congenic strain suggests a locus at the distal end of the 54 Mb interval acting at 
(9 wk) “later” locus  




an early stage of atherogenesis. (C) After 9-wk WTD feeding, 17-Mb and 11-Mb 
subcongenic strains revealed increased susceptibility for atherosclerosis, suggesting an 
additional locus located in the proximal region of the 54 Mb interval. A 4-Mb interval at 
the proximal tip of the full interval does not confer increased susceptibility for 
atherosclerosis. ANOVA was performed with square root transformation. Horizontal bars 
indicate mean values for males (blue) and females (red) for each genotypic group. NS, 
not significant. D) Prominent versican accumulation in the 17-Mb congenics compared to 
the controls after 9-wk WTD feeding. 
 
Conserved chromosomal homology between the Athsq1 proximal locus and 
human chr 9p21 including a widely-replicated CHD locus. The endpoints of the 
proximal susceptible interval were defined by microsatellite marker.genotyping. As 
shown in Figure 2-3, the minimal interval is defined by markers D4Mit27 and D4Mit350 
(88.7 - 94.1 Mb). The maximal interval is defined by markers D4Mit349 and D4Mit154 
(87.4 - 96.4 Mb) (Figure 2-3, B). The interval contains 8-21 known protein coding 
genes/gene families (Figure 2-3, A). Comparative analysis of mouse and human 
homologies revealed that the proximal Athsq1 interval overlaps the region of homology 
with the human CHD locus on chr 9p21 (Figure 2-3, C). The closest protein coding 
genes transcribed from the CDKN2A/B locus are conserved in mouse and human. Thus, 






Figure 2-3 The proximal Athsq1 locus harbors 8-21 genes and contains the region of 
homology with a human CHD risk interval on chr 9p21 
(A) List of genes residing in the Athsq1 proximal interval (taken from the Mouse Genome 
Informatics Database, MGD). (B) Schematic of the 5.4 – 9 Mb interval defined by 
microsatellite markers. The white rectangle denotes the minimally mapped susceptibility 
locus derived from MOLF/Ei. Recombination breakpoints occur between 
D4Mit349/D4Mit27 (proximal end) and D4Mit350/D4Mit154 (distal end). The black 
rectangles denote alleles derived from B6. (C) Magnification of the area containing the 
region of homology with a human CHD risk interval on 9p21 (shown in red). The 
orientation of flanking genes is shown with blue boxes.  
 
Accelerated atherosclerosis in the Athsq1congenic mouse is mediated, at least in 
part, by BM-derived cells. BM transplantation studies are frequently performed to 




models of atherosclerosis (168). In order to identify the cell type(s) responsible for the 
pro-atherogenic phenotype of the Athsq1congenic mice, we performed a series of BM 
transplantation experiments. To test the role of BM-derived cells, lethally-irradiated B6-
Ldlr-/- recipient mice were injected with donor BM derived from the congenic or 
noncongenic mice (both on the B6-Ldlr-/- background). After recovery/repopulation of the 
BM-derived cells with donor cells, mice were fed 11-wk WTD and atherosclerotic lesions 
were analyzed from the proximal aorta. Lesion area was significantly increased in mice 
receiving congenic (51 Mb)- derived BM compared to mice receiving noncongenic (b/b) 
BM (p=0.0016; Figure 2-4,A). Greater accumulation of versican in mice receiving 
congenic-derived BM was also observed (Figure 2-4,B-C): a 2.5-fold increase in 
versican-positive medial area (Figure 2-4,D) in mice receiving congenic BM compared to 
the controls. These results indicated that BM-derived cells play an important role in the 




Figure 2-4 Increased lesion area and versican accumulation in B6-Ldlr -/- mice 




(A) Atherosclerotic lesion area after 11-wk WTD feeding of B6-Ldlr -/- mice receiving b/b 
or 51-Mb BM. Horizontal bars represent group means. (B, C) Representative cross-
sections including atherosclerotic lesions derived from BM-transplanted mice 
immunostained with versican (red). Pl, plaque; M, media (D) Quantification of versican-
positive medial area by morphometric analysis shown in (B, C). Data analyzed by t-test 
with square root transformation. Female B6-Ldlr-/- mice were used as recipients.  
 
A reciprocal BM transplantation study was performed to determine whether 
vascular wall cells, including SMCs or ECs, contributed to the pro-atherogenic 
phenotype conferred by the proximal locus. BM derived from B6-Ldlr-/- controls was 
injected into lethally-irradiated 17-Mb congenic and non-congenic controls. Following 
repopulation of the BM, mice were fed 11-wk WTD and analyzed for atherosclerotic 
lesion development. No differences in mean lesion areas were observed for males or 
females, or both sexes combined (Figure 2-5). Importantly, these data indicate that 
vascular wall-derived cells, ECs and/or SMCs, are not involved in the accelerated 
atherosclerosis phenotype associated with this locus. Thus, we focused further 





Figure 2-5 Vascular cells from the Athsq1 congenic mice do not contribute to the pro-
atherosclerotic phenotype conferred by the proximal locus. 
Mean lesion areas from a reverse BM transplantation study in which both control (b/b) 
and subcongenic  (17-Mb) recipients received BM from B6-Ldlr-/- mice. Following 
repopulation of the BM, mice were fed 11-wk WTD. ANOVA was performed with square 
root transformation. Horizontal bars indicate mean values for males (blue) and females 
(red) for each genotypic group. NS, not significant. 
 
Discussion 
Generation of subcongenic strains derived from the full congenic Athsq1 strain 
revealed at least two loci in the Athsq1 interval: 1) a distal locus acting early in lesion 
development (6-wk WTD feeding) and 2) a proximal locus acting at a later stage (9wk-
WTD feeding). Moreover, BM transplantation studies revealed that BM-derived cells are 
responsible for the accelerated atherosclerosis phenotype seen in the congenics.  
Gene(s) that are located in the distal locus likely play a role in initiation of 
atherogenesis including activation of the endothelium, leukocyte recruitment, monocyte 
migration into the intima, or foam cell formation. The gene(s) located in the proximal 
locus likely act at later events such as inflammatory cell proliferation (reviewed in (9)). To 
accurately define what stage the loci act during atherosclerosis development, the 
atherosclerotic lesions should be categorized carefully according to the morphologic 
features, for example, lesion size, necrotic core area and lesional cap thickness etc. This 
would assist in clearly defining the phases of genes/loci that come into action during 
atherosclerosis development.  
Comparative mapping of mouse and human chromosomes revealed that the 
narrowed proximal locus contains the region of homology with the human CHD locus on 
9p21 (91-94). Moreover, fine mapping of the locus narrowed the list of candidate genes 




overlaps a long non-coding RNA, ANRIL, with the closest protein coding genes 
transcribed from the CDKN2A/B locus. These protein coding genes are involved in cell 
cycle regulation and are key tumor suppressor genes (169, 170). The proteins encoded 
by CDKN2A/B function as inhibitors of cell proliferation (Fig 1.) The binding of p15INK4b 
(encoded by CDKN2B) and p16INK4a (encoded by CDKN2A) to cyclin dependent kinase 
4/6 (CDK4/6) blocks the assembly of catalytically active cyclin D–CDK complexes, 
inhibiting CDK4/6- mediated phosphorylation of retinoblastoma (Rb), leading to G1 cell 
cycle arrest (169, 171). 
The tumor suppressor activity of p14ARF (mouse p19ARF, encoded by CDKN2A) is 
largely ascribed to its ability to regulate p53 in response to aberrant growth or oncogenic 
stress, thus leading to apoptosis when p14ARF is present (169, 171). It has been 
hypothesized that regulatory elements underlie the associated CHD locus, regulating the 
expression of CDKN2A/B genes (104, 105, 108, 166, 172). Thus, the accelerated 
atherosclerosis observed in the congenics might be due to increased proliferation of 
vascular cells, including ECs, SMCs or macrophages. Since the BM transplantation 
study revealed that BM-derived cells, but not resident vascular wall cells, are critical for 
atherogenesis in the congenics, we hypothesized that the accelerated phenotype 
observed in the congenics is due to increased proliferation of BM-derived cells.  
Atherogenesis is initiated by lipoprotein retention and modification, ECM deposition, 
and inflammatory cell recruitment. Versican, a presumed proatherogenic ECM protein 
was examined to confirm the previous findings that versican accumulation segregates 
with increased atherosclerosis. Analysis of ECM composition in the 17-Mb congenic 
mice and BM-transplanted animals receiving 51-Mb congenic BM revealed prominent 




intimal thickenings as well as advanced lesions (173). Versican binds LDL particles with 
high affinity and increases LDL atherogenicity (174). Due to the structure of versican, it 
has been speculated that accumulation of versican in the vessel wall may promote both 
extracellular lipoprotein retention and intracellular lipid uptake leading to foam cell 
formation (175). Versican-hyaluronan complexes promote macrophage adhesion 
through cell surface receptors and cell adhesion molecules. This would presumably lead 
to the depoition of a proatherogenic matrix in the Athsq1 congenics. 
The distal end of the Athsq1 locus, defined by the Sub-B strain, contains a 34.1 Mb 
interval harboring ~520 annotated genes. The large number of genes prohibits any 
meaningful discussion of potential candidate genes. Since the Athsq1 locus (54-Mb) is a 
large interval, we cannot exclude the possibility that there are genes having opposing 
effects. Among the genes residing in the narrowed 5.4-9 Mb interval interval, type I - 
interferon (IFN-I) family is worthy of note. Elevated levels of IFN-I (including IFN-α and -β) 
(176) have been observed in patients with systemic lupus erythematosus (SLE). High 
levels of IFN-I results in endothelial progenitor cell depletion and dysfunction thus 
leading to increased cardiovascular risk in SLE patients (177). Goossens et al (178) 
have shown that IFN-I induces chemotactic factors and enhances macrophage adhesion 
in vitro. IFN-β promotes macrophage, but not neutrophils or T-cell content, in 
atherosclerotic carotid arteries of Apoe-/- mice. BM lacking IFN-I reduces atherosclerosis 
development (178). These studies have provided evidence that IFN might be a potential 
candidate gene. Further analysis, including sequencing, expression, and functional 
studies of the gene will be required to determine if genes of the IFN-Ifamily located in the 
5.4-9 Mb interval is another culprit gene. 




congenics is intriguing. BM cells are precursors of peripheral blood mononuclear cells 
(PBMCs). PBMCs play a critical role in inflammation during atherogenesis and constitute 
a major cellular component of atherosclerotic lesions. Using PBMCs from patients with 
severe carotid atherosclerosis, gene expression analyses revealed of a number of 
regulatory genes and transcription factors that were altered in patients compared with 
controls without measurable disease (179). Genomic signatures derived from BM 
progenitor cells differentiate between vascular damage and restoration in mice and were 
homologous to those seen in humans (180). These studies validate genomic gene sets 
discovered in the mouse and provide potential applications to human disorders. Thus, 
gene expression profiling using PBMCs should provide further insights into the 
underlying mechanism for acclererated atherolscerosis observed in congenic and 










Chapter 3. Cdkn2a is an Atherosclerosis Modifier Locus That 





Objective: GWAS studies have been fruitful in identifying genetic variant loci underlying 
complex traits. The most highly replicated locus for CHD is on chr 9p21.3. However, the 
functional link between genetic variants and disease remains to be understood.  
Methods and Results: We have localized a murine atherosclerosis susceptibility locus 
to a region of chr 4 containing 8-21 genes/gene families, including Cdkn2a/b. In the 
current study, mRNA expression analyses in macrophages showed markedly decreased 
Cdkn2a (cyclin-dependent kinase inhibitor 2a) transcript expression, including both 
p16INK4a and p19ARF, but not Cdkn2b (p15INK4b), in cells from susceptible congenic mice 
compared to controls. Interestingly, the congenic mice also exhibited increased 
circulating levels of Ly6Chi inflammatory monocytes compared to controls. To directly 
test the role of BM-derived Cdkn2a transcripts in atherogenesis and inflammatory cell 
proliferation, we performed a BM transplantation study utilizing Cdkn2a+/- cells in the Ldlr-
/- mouse model. Cdkn2a+/- recipients exhibited accelerated atherosclerosis, increased 
inflammatory monocyte subsets and increased monocyte/macrophage proliferation 
compared to controls. 
Conclusions: We have used an unbiased mouse genetics approach to identify the 
Cdkn2a locus as a modifier of atherosclerosis susceptibility through altered expression 
in monocyte lineage cells. The data provide a novel mechanistic link between decreased 
expression of Cdkn2a transcripts, increased monocyte/macrophage proliferation, 






GWASs have identified numerous genetic variants associated with complex traits (75-
84). Some of the susceptibility variants lie outside of coding regions, and are assumed to 
influence transcript regulation rather than gene function. Recent studies in animal 
models (139, 166, 167, 172, 181, 182)  have shed light on the  genetic variants identified 
by GWASs, stressing the importance of model organisms.  
The most highly replicated risk locus for CHD (including MI, stroke and aortic 
aneurysm) is on chr 9p21.3, accounting for a substantial part of atherosclerotic risk in 
the general population(91-93). The association at 9p21 appears to be the strongest 
common (minor allele frequency > 10%) genetic determinant in the human genome, yet 
the association is independent of traditional risk factors for athero-thrombotic disease, 
such as plasma cholesterol levels and hypertension. The SNPs most strongly associated 
with disease risk map to a 58-kb region that includes a long, non-coding RNA (ANRIL) 
but is devoid of known coding genes (Figure 1-4). Individuals carrying the risk allele 
have been shown to exhibit decreased expression of p16INK4a, p19ARF, and p15INK4b -
inhibitors of cellular proliferation encoded by the nearby CDKN2A/B locus – as well as 
proximal transcripts of ANRIL, in some studies (104-106) but not others (107, 108). 
Targeted deletion of the homologous region in mice resulted in markedly decreased 
expression of all three transcripts encoded by the Cdkn2a/b locus, and increased 
proliferation of vSMCs in vitro, but effects on atherosclerosis were not reported (166) 
Thus, the role of these transcripts and the pathogenic mechanism leading to increased 
atherosclerotic risk remains unclear. 
We previously performed refined genetic mapping of a murine atherosclerosis 




homology with the human 9p21 CVD locus. In the current study, gene expression 
studies revealed decreased mRNA levels of p16INK4a and p19ARF, but not p15INKb4, in 
macrophages derived from susceptible congenic mice compared to controls. As we had 
previously shown that BM-derived cells were capable of conferring the pro-atherogenic 
phenotype of the congenics, we investigated the hypothesis that reduced expression of 
Cdkn2a cell proliferation inhibitor transcripts in BM-derived cells leads to accelerated 
atherosclerosis via increased proliferation of inflammatory monocyte/macrophages. 
Materials and Methods 
Mice. B6.MOLF-Athsq1 congenic mice were bred using marker-assisted congenic strain 
production as described (162) and chapter 2 herein. B6.129S7-Ldlrtm1Her (B6-Ldlr–/–) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). Subcongenic mice 
were derived from the 54-Mb strain; recombinants were identified and intercrossed at the 
N14 generation. B6-Cdkn2a-/- mice were a kind gift of Dr. Sean Morrison (University of 
Michigan). The targeted mutation replaced exons 2 and 3 with a neo cassette, therefore 
knocking out both p16INK4a and p19ARF. Mice were bred to B6-Ldlr–/– mice in our colony. 
Mice were fed WTD containing 21% milk fat and 0.15% cholesterol (TD 88137, Harlan 
Teklad) for the indicated time periods before sacrifice. All procedures were in 
accordance with institutional guidelines. 
DNA extraction and genotyping. DNA was extracted from tail tips, and microsatellite 
markers and Ldlr alleles were typed by polymerase chain reaction (PCR) as previously 





Gene expression profiling. Peritoneal monocyte/macrophages were isolated from B6-
Ldlr-/-or 54-Mb congenic mice three days after no treatment (resident) or intra-peritoneal 
injection of concavalin A to elicit monocytes to the peritoneal cavity. Cells were plated 
and washed one hour later to remove non-adherent cells, followed by overnight 
incubation in DMEM (Dulbecco's modiﬁed Eagle's medium, 25 mM glucose), 10%FBS, 
and 1% penicillin/streptomycin. Splenic monocyte/macrophages were isolated to >90% 
purity by Magnetic Activated Cell Sorting (MACS) using an anti-CD11b antibody (Miltenyi) 
as described (104, 183).RNA was isolated using an RNA micro kit (Qiagen) according to 
the manufacturer’s protocol.  
Microarray analysis was performed as described (184). Merck/Affymetrix mouse 1.0 
custom arrays monitoring 38,384 individual transcripts (25,846 Entrez genes, NCBI build 
37) were used. Raw intensity was normalized using the robust multi array average 
algorithm (185). ANOVA analysis identified differentially expressed genes using a 1.2-
fold change threshold (congenics vs controls, p< 0.05). Raw data were deposited in the 
NCBI gene expression and hybridization array data repository, GEO and are available 
under accession # GSE 24342. 
Transcript-specific real-time PCR. Transcript-specific real-time PCR (rtPCR) was 
performed to confirm results. Briefly, 1 µg of purified total RNA was used for reverse 
transcription with SuperScript II Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. Transcript expression was measured using TaqMan 
strategies specific for p16INK4a, p19ARF, p15INK4b, and other indicated transcripts as 




Atherosclerotic Lesion Measurements. Paraffin-embedded serial sections were 
prepared from the aortic root as described (157, 162). Lesion area was quantified by 
morphometric analysis of H&E stained sections, and average lesion size determined 
from six sections per mouse. 
BM Transplantation. Irradiated recipient B6-Ldlr–/– mice injected with either B6-Ldlr+/- or 
B6-Ldlr+/-, Cdkn2a+/- BM. Reconstitution of the BM with donor cells was confirmed at six 
weeks (wks) post-injection with microsatellite markers for the congenic interval or allele-
specific Cdkn2a and Ldlr primers, respectively. Mice were then fed 10-11 wk WTD 
before euthanasia. 
Bromodeoxyuridine (BrdU) labeling. Mice were injected intraperitoneally with 200 ul of 
2 mg BrdU/mouse. The pulse was 18 hrs for the analysis of circulating monocytes in the 
BM transplantation experiment. The dose and duration were based on studies 
investigating the proliferative activity of murine monocytes(187, 188). To assess 
proliferation of tissue macrophages, a longer BrdU dosing protocol was used. For 
assessment of peritoneal macrophage proliferation, cells were harvested after three 
consecutive injections of BrdU over 72 hrs following a 24-hr concavalinA injection. 
 Flow cytometry analysis. Flow cytometry analysis was performed as previously 
described (25). Briefly, 100 µl of blood was collected into EDTA tubes followed by red 
blood cell lysis. Cells were washed with HBSS (Hank's Buffered Salt Solution, 0.1% BSA 
w/v, 5 mM EDTA) and stained on ice using an antibody cocktail including CD45-APC-
Cy7 (pan –leukocytes), CD115-APC (monocytes),Ly6C-PerCP (monocyte subsets), and 
BrdU-FITC (all from BD Pharmingen). Monocytes were identified as CD45+ CD115+ cells 




Peritoneal monocyte/macrophages were freshly collected and stained with CD45,CD115 
and F4/80-PE (mature macrophage marker). Multiparameter analyses were performed 
using a BD LSR II flow cytometer (Becton Dickinson) with DiVa software. Data were 
analyzed using FlowJo software (Tree Star, Inc.). 
Statistical analysis. ANOVA and t tests were performed using STATVIEW 5.0 (Abacus 
Concepts,Inc). Both males and females were included in lesion analyses using genotype 
and sex as factors in the ANOVA. The threshold for significance was p <0.05. Data 
shown are mean ± SD or SEM, as indicated. 
Results 
Decreased macrophage expression of p16INK4a and p19ARF, but not p15INK4b, in the 
Athsq1 congenic mice. In parallel to the mapping effort, we performed microarray 
analysis to narrow down the list of candidate genes in the atherosclerosis susceptibility 
subcongenic interval. Gene expression analysis was performed to search for genes that 
are differentially expressed between the congenics and controls. Elicited peritoneal 
macrophages derived from full (54-Mb) congenics and non-congenic controls were 
collected after 6-wk WTD feeding. Differentially-expressed genes were defined as 
exhibiting 20% difference in expression level with a significance threshold corrected for 
multiple testing (184). Only 2-8 of the differentially expressed transcripts reside within 
the narrowed 5.4-9-Mb interval and could be considered as causal candidate genes 
(Table 3-1). Strikingly, the most significant difference was a ~6-fold decrease in Cdkn2a 
levels in congenic compared to control macrophages. Cdkn2a encodes two transcripts 




Table 3-1 Cdkn2a is the most differentially expressed macrophage-derived gene 
residing in the 5.4-9-Mb mapped susceptibility interval. 








Klhl9 kelch-like 9  88.3 1.29 0.0001 
Ptplad2 protein tyrosine phosphatase-like A 
domain containing 2  
88.0 1.24 0.0065 
Mtap methylthioadenosinephosphorylase 88.8 -1.26 7.77E-05 
Ptplad2 protein tyrosine phosphatase-like A 
domain containing 2  
88.0 -1.30 0.0071 
Jun Jun oncogene 94.7 -1.39 0.0028 
Tusc1 tumor suppressor candidate 1  93.0 -1.88 5.36E-07 
Cdkn2a cyclin-dependent kinase inhibitor 
2A  
88.9 -5.98 1.25E-06 
Fold-change listed for all transcripts encoded within the 5.4-9-Mb interval and exhibiting 
a ≥20% difference in expression level in peritoneal macrophages derived from Athsq1 
54-Mb full congenic or non-congenic mice fed 6-wk WTD. N = 10 mice/group. Note that 
Ptplad2 is listed twice (+1.24, -1.30 fold changes), likely the result of splice variants 
occurring within the array. 
On the right is a schematic of the 5.4-9-Mb narrowed susceptibility interval with 
microsatellite markers, and the corresponding genome coordinates in megabases (Mb). 
The white rectangle denotes the minimally mapped susceptibility locus derived from 
MOLF/Ei. The black rectangles denotes alleles derived from B6. 
 
The two transcripts from the Cdkn2a locus-p16INK4a and p19ARF utilize different 
promoters and alternative reading frames resulting in proteins with no amino acid 
homology(169). Because of the Cdkn2a exonicstucture, the microarray could not discern 
p16INK4a vs p19ARF transcripts. Therefore, we further examined Cdkn2a expression using 




Expression of both p16INK4a and p19ARF, but not the adjacent p15INK4b transcript, were 
reduced in macrophages from the atherosclerosis-prone 54- and 17-Mb congenics 
compared to non-congenic controls (Figure 3-1, A). Similar results were observed for 
both transcripts in resident peritoneal macrophages, and for p16INK4a in splenic 
monocyte/macrophages, from 54- and 17-Mb congenic mice compared to controls 
(Figure 3-1, B-C). Thus, an atherosclerosis-prone murine strain, identified through an 
unbiased genetic screen, exhibits decreased expression of the p16INK4a and p19ARF 





Figure 3-1 Decreased expression of p16INK4a and p19ARF, but not p15INK4b, cell 
proliferation inhibitor transcripts in BM-derived cells from Athsq1congenic mice 
compared to controls. 
Transcript-specific rtPCR results for Cdkn2a (p16INK4a and p19ARF) and Cdkn2b (p15INK4b) 
expression in (A)concavalin A-elicited peritoneal macrophages, (B) resident peritoneal 
macrophages, or (C)splenic CD11b+monocyte/macrophages derived from B6-Ldlr-/- (b/b) 
or subcongenic (17-Mb) mice fed 6-wk WTD. ANOVA performed with log transformation. 





Expansion of the circulating Ly6Chi inflammatory subset of monocytes in 17-Mb 
congenics compared to controls. To test potential atherogenic mechanisms 
consistent with decreased p16INK4a and/or p19ARF expression, we assessed monocytosis 
in 17-Mb subcongenics and controls. No differences were observed in circulating white 
blood cell counts or total monocytes in blood derived from 54-Mb congenics compared to 
controls (Figure 3-2, A-D). Pro-inflammatory monocyte subsets have been associated 
with hypercholesterolemia and CHD events (35, 37, 38). Therefore we further 
investigated monocyte subsets by using a Ly6C antibody to differentiate inflammatory 
monocytes (Ly6Chi) vs patrolling monocytes (Ly6Clo). We observed increased 
percentages of Ly6Chi, and decreased Ly6Clomonocyte subsets in congenics compared 
to controls after 3- (pre-lesional), 6- and 9-wk WTD feeding (Figure 3-3, A-B). This 
resulted in an increased ratio of Ly6Chi: Ly6Clo monocytes in the circulation (Figure 3-3, 
C). These data suggested that expansion of the Ly6Chi inflammatory subset of circulating 
monocytes might underlie the accelerated atherosclerosis phenotype of the 17-Mb 
congenic mice. This mechanism is consistent with decreased expression of p16INK4a 
and/or p19ARF, the latter of which has been shown to regulate macrophage proliferation 





Figure 3-2 No differences in white blood cell counts in the circulation of 54-Mb 
congenics compared to non-congenic controls. 
White blood cell counts were measured after 4- , 8- and 15-wk WTD feeding. No 
differences were observed in the levels of (A) total white blood cell counts, (B) 





Figure 3-3 Expansion of the inflammatory Ly6Chimonocyte subset in the circulation of 
17-Mb congenics compared to non-congenic controls. 
(A) Flow cytometry analysis of blood monocytes after various periods of WTD feeding. 
Note that the 3-wk timepoint is pre-lesional. Monocytes were gated as CD45+CD115+ 
Ly6Chi or CD45+CD115+Ly6Clo cells and representative scatter plots for each timepoint 
are shown. (B) Quantification of the percentages of Ly6Chi and Ly6Clo monocytes among 
total CD45+CD115+ cells in control (b/b) and 17-Mb subcongenics. (C) Ratio of Ly6Chi: 
Ly6Clo monocyte subsets in the circulation after various periods of WTD feeding. Data 





Heterozygous deletion of Cdkn2a in BM-derived cells results in accelerated 
atherosclerosis, expansion of the Ly6Chi monocyte pool, and increased BrdU 
incorporation into monocytes and macrophages. To directly test the hypothesis that 
decreased Cdkn2a expression in BM-derived cells is pro-atherogenic, we performed a 
BM transplantation study using a previously described Cdkn2a-deficient mouse. The 
targeted mutation replaces exons 2/3 with a neo cassette, knocking out both p16INK4a 
and p19ARF expression (190), and has been crossed into a uniform B6 background. In an 
effort to simulate the two- to four-fold reduction of p16INK4a and p19ARF expression 
observed in congenics compared to controls, we used donor B6-Ldlr+/-mice 
heterozygous for the Cdkn2a allele. Lethally irradiated B6-Ldlr-/- recipients were injected 
with BM derived from B6-Ldlr+/- or B6-Ldlr+/-, Cdkn2a+/- mice. Following repopulation of 
the BM, mice were fed 10-wk WTD. No differences were observed in body weight, 
plasma total cholesterol, HDL or triglycerides (Table 3-2).  
Table 3-2 Body weight and plasma lipoprotein profiles of B6-Ldlr-/-mice receiving Ldlr+/-












Ldlr+/-  26.5±3.1 1230±339 83±22 445±12 1147±338 
Ldlr+/- , Cdkn2a+/-  26.4±4.4 1363±229 82±14 424±11 1276±232 
Mice were fed 10-wk WTD. Data are mean ± SD, n=17-19/group. Abbreviations: BWT, 
body weight; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, 





Resident peritoneal macrophages exhibited a 2.5-fold decrease in expression of p16INK4a 
but not p19ARF or p18INK4c (another INK4-class gene encoded by a distant region of 
mouse chr 4) in B6-Ldlr+/-, Cdkn2a+/- recipients compared to controls (Figure 3-4,B). 
Similarly, splenic CD11b+monocyte/macrophages exhibited ~4-fold decreases in both 
p16INK4a and p19ARF but not p18INK4c (Figure 3-4,C). Importantly, mean atherosclerotic 
lesion area was increased 34% and 17%, in males and females respectively, in B6-Ldlr+/-, 
Cdkn2a+/- recipients compared to controls (p < 0.05 for combined data) (Figure 3-4, A). 
Thus, heterozygous deficiency of Cdkn2a in BM-derived cells is sufficient to confer an 





Figure 3-4 Heterozygous deficiency of Cdkn2a in BM-derived cells is sufficient to 
promote atherosclerosis in the B6-Ldlr-/- mouse model. 
(A) Mean lesion areas from lethally-irradiated B6-Ldlr-/- mice injected with BM derived 
from B6-Ldr+/-, Cdkn2a+/- or B6-Ldr+/- mice. Following repopulation of the BM, mice were 
fed 10-wk WTD. ANOVA performed with square root transformation. Horizontal bars 
indicate mean values for males (circles) and females (triangles) for each genotypic 
group. (B-C) Transcript-specific rtPCR results for Cdkn2a (p16INK4a and p19ARF) and 
p18INK4c (another INK4-class gene encoded by a distant region of mouse chr 4) 
expression in (B) resident peritoneal macrophages or (C) splenic CD11b+ 
monocyte/macrophages. ANOVA performed with log transformation. Data are shown as 




We determined whether the increased lesion area in mice receiving Cdkn2a+/- BM 
was associated with elevated levels of versican accumulation. Vesican staining in mice 












Figure 3-5). We then investigated whether the pro-atherosclerotic mechanism 
involved apoptosis or monocytosis. TUNEL staining of atherosclerotic lesions revealed 
few positive cells and no difference between B6-Ldlr+/-, Cdkn2a+/- recipients compared to 
controls (data not shown). However, flow cytometry analysis of blood monocytes 
revealed an expansion of the Ly6Chi subset in B6-Ldlr+/-, Cdkn2a+/- recipients similar to 
that observed in the 17-Mb congenics. Increased percentages of Ly6Chi and decreased 
percentages of Ly6Clo subsets were observed in B6-Ldlr+/-, Cdkn2a+/- recipients 
compared to controls at each timepoint (0-10 wk  WTD feeding) (Figure 3-6, A-B). This 




circulation (Figure 3-6,C). To test for a direct effect of heterozygous Cdkn2a deficiency 
on monocyte proliferation, we injected mice with BrdU before sacrifice at the 10-wk 
timepoint. B6-Ldlr+/-, Cdkn2a+/- recipients exhibited an increase in the percentage of 
BrdU+ monocytes compared to controls, indicating increased monocyte proliferation 
(Figure 3-6,D-E). Moreover, the increase in BrdU incorporation occured mainly in the 













Figure 3-5 No difference in versican staining in mice receiving Cdkn2a+/+ or Cdkn2a+/-BM. 
Prominent accumulation of versican was observed at the media: intima interface of 
plaques in some mice receiving either (A) Cdkn2a+/+ or (B) Cdkn2a+/- BM.  
 





Figure 3-6 Expansion of the inflammatory Ly6Chi monocyte subset, mediated by 
increased cell proliferation, in the circulation of B6-Ldlr-/- mice transplanted with Ldlr+/-, 




(A) Flow cytometry analysis of blood monocytes from Ldlr+/-, Cdkn2a+/- or Ldlr+/- BM 
recipients after various periods of WTD feeding. (B)Monocytes were gated as 
CD45+CD115+ Ly6Chi or CD45+CD115+Ly6Clo and representative scatter plots for each 
timepoint are shown. (C) Increased ratio of Ly6Chi: Ly6Clo monocytes in the circulation of 
B6-Ldlr-/- mice injected with BM derived from B6-Ldr+/-, Cdkn2a+/- mice compared to 
controls injected with B6-Ldr+/- BM. Blood was collected following 0-10 weeks of WTD 
feeding. (D) Quantification of the percentages of Ly6Chi and Ly6Clo cells among total 
CD45+CD115+ cells. (E) Analysis of proliferating CD45+CD115+ monocytes at the 10-wk 
timepoint. Cells were gated as Ly6ChiBrdU+ and representative plots are shown. E, 
Quantification of the percentage of BrdU+ cells among total CD45+CD115+ monocytes. 
Data are shown as mean ± SEM. *p ≤ 0.05, **p ≤ 0.005, †p ≤ 0.0005. 
 
To test for an effect of BM-derived Cdkn2a deficiency on tissue macrophage 
proliferation, we assayed concavalin A-elicited peritoneal macrophages by flow 
cytometry following intraperitoneal BrdU injection. While there was no difference in the 
total number of CD45+CD115+F4/80+ macrophages (Figure 3-7, A), there was a 
significant increase in the percentage of macrophages staining positive for BrdU in B6-
Ldlr-/-, Cdkn2a+/- mice compared to B6-Ldlr-/- controls (p < 0.04) and a trend in the 17-Mb 
congenics compared to controls (p = 0.1) (Figure 3-7, B-C).Together, these data provide 
direct evidence for a suppressive effect of p16INK4a and/or p19ARF expression in BM-






Figure 3-7 Increased proliferation of peritoneal macrophages derived from B6-Ldlr-/- 
mice transplanted with Ldlr+/-, Cdkn2a+/- BM compared to controls. 
(A) Flow cytometry analysis of concavalin A-elicited macrophages from B6-Ldlr-/-, 17-Mb 
congenic, or B6-Ldlr-/-, Cdkn2a+/- mice after 4-5 wks of WTD feeding.Macrophages were 
gated as CD45+CD115+F4/80+ and representative scatter plots for each genotypic group 
are shown. (B) Analysis of proliferating CD45+CD115+F4/80+ macrophages at the 4-5 wk 
timepoint. Cells were gated as BrdU+ and representative plots are shown. (C) 
Quantification of the percentage of BrdU+ cells among total CD45+CD115+F4/80+ 
macrophages. Data are shown as mean ± SEM. *p ≤ 0.05 
 
Discussion 
 Prior to the identification of 9p21 as a risk locus for human CVD, we used an 




a modifier of atherosclerosis susceptibility in chapter two. In the current study, we show 
that Cdkn2a mediates some or all of the altered atherosclerosis susceptibility of this 
region through altered transcript expression in monocyte/macrophages. In support of this 
model, heterozygous deficiency of Cdkn2a transcripts in BM-derived cells was found to 
be sufficient to confer accelerated atherogenesis in the B6-Ldlr-/- background. The 
modest (~2-4-fold) reduction in p16INK4a and p19ARF expression associated with 
increased atherosclerosis in these murine models is consistent with the reduction of 
p16INK4a and p19ARF expression in carriers of the 9p21 risk allele (104). Along with other 
data (104, 105, 166, 172), this strongly suggests that decreased expression of p16INK4a 
and/or p19ARF may be responsible for the accelerated atherosclerosis associated with 
chr 9p21 in humans. Moreover, our study strongly suggests that the underlying 
pathogenic mechanism involves increased proliferation/expansion of the Ly6Chi 
inflammatory monocyte subset in the circulation as well as increased proliferation of 
tissue macrophages. This provides a plausible mechanism to account for accelerated 
atherogenesis and, possibly, other vascular phenotypes associated with 9p21 in humans 
(see below). 
 Consistent with our BM transplantation experiment, whole body p19ARF- deficiency 
was recently shown to be pro-atherosclerotic in the B6-Apoe-/- background (172). The 
mechanism of action suggested in the Apoe-/- model was decreased apoptosis, although 
the culprit cell type was not identified. We did not observe differences in apoptosis in 
either the Athsq1congenic model or mice carrying BM-deficiency of Cdkn2a compared to 
respective controls. The discrepancy between the two studies could be due to different 
experimental designs (BM vs whole body deficiency) or mouse models (Ldlr-/- vs Apoe-/-). 




lesions, likely resulting in increased plaque vulnerability to rupture. Thus, while 
decreased apoptosis may accelerate early lesion formation, increased apoptosis likely 
contributes to lesion progression to advanced plaques with clinically significant 
consequences(191). 
Evidence for an association between elevated WBC counts and CVD risk has 
been documented in more than a dozen prospective epidemiological studies (192). In 
particular, high levels of circulating CD14+CD16+ inflammatory monocytes have been 
associated with hypercholesterolemia (36) and CAD events (39). There is also 
substantial evidence in animal models for a causal relationship between monocytosis 
and atherogenesis (193-196). In mouse models of diet-induced atherosclerosis, the 
subset of Ly6Chi expressing monocytes expands with hypercholesterolemia and 
selectively enters sites of inflammation including atherosclerotic lesions, compared to the 
Ly6Clo subset (54, 187). In addition, single gene mutations resulting in reduced blood 
monocytes also reduced atherosclerosis independent of plasma cholesterol levels (197-
200). While the relationship between monocytosis and atherosclerosis has been well-
documented, detailed mechanisms are lacking. Consistent with a recent finding (25), our 
study suggests that the control of myeloid cell proliferation during hypercholesterolemia 
is an important factor determining magnitude of leukocytosis and the atherogenic 
response. 
Regulation of CDKN2A/B gene expression by the 9p21 CVD locus in humans is 
unknown. It has been suggested to occur via cis or trans mechansim(s) involving either 
the structurally overlapping non-coding RNA, ANRIL(106, 201), or other regulatory 
motifs residing within the 58-kb risk locus (108, 167). The mouse genome does not 




expression of Cdkn2a/b transcripts in the 70-kb deletion mutant suggests the existence 
of a cis-acting enhancer (166). Expression of CDKN2A/B transcripts are highly 
correlated in humans (106, 183). In our Athsq1 congenic mouse, there is a loss of 
coordinate regulation with decreased expression of Cdkn2a (p16INK4a and p19ARF) 
transcripts compared to non-congenic controls but not Cdkn2b (p15INK4b). Thus, the 
causal variant is likely to be cis-acting and specific to the Cdkn2a locus. 
 The 9p21 locus has been associated with multiple vascular phenotypes. These 
include myocardial infarction (91), abdominal aortic and intracranial aneurysms (98), 
ischemic stroke (202, 203) and peripheral artery disease (204). In mice, mutations in 
monocyte/macrophage chemoattractants or their receptors, such as monocyte 
chemoattractant-1 (Ccl2 in mice; MCP1 in humans) and fractalkine receptor-1 (Cx3cr1), 
result in reduced blood monocyte counts and proportionate reductions in atherosclerosis 
(199). Interestingly, monocyte/macrophage recruitment is an important process in 
cerebral aneurysm formation and Ccl2 deficiency has been shown to inhibit macrophage 
accumulation in aneurysmal walls and significantly decrease aneurysm formation in an 
experimentally induced mouse model (205). In another study, increased immune-
positivity for CD68 antigen was observed in intracranial aneurysms compared to control 
tissue (206). In ischemic stroke, macrophage accumulation has been associated with 
severity of brain injury (207). Thus, alterations in monocyte/macrophage proliferation 
may provide a common underlying mechanism for vascular phenotypes associated with 















The goal of this thesis was to fine map the Athsq1 locus and elucidate the 
mechanism(s) leading to atherosclerosis. Here we report refined mapping of the Athsq1 
locus by creating a series of subcongenic strains and identify the existence of two 
susceptibility loci within the interval, with BM-derived cells shown to play an important 
role for the accelerated atherosclerosis. The proximal interval was further narrowed to a 
genomic region containing 8-21 genes, including the region of homology with a human 
CHD risk interval on chr 9p21, with Cdkn2a as a candidate locus within the interval. 
Interestingly, macrophages exhibited markedly decreased Cdkn2a (p16INK4a and p19ARF) 
expression in congenic mice compared to controls. Gene-targeted knockout alleles of 
tumor suppressor/cell cycle regulation genes (p16INK4a and p19ARF) in BM-derived cells 
lead to increased atherosclerosis, monocyte/macrophage proliferation and expansion of 
Ly6Chi inflammatory monocytes. These findings provide a potential mechanism to 
explain the most consistent and striking new genetic marker for arterial disease risk 
emerging from GWASs. 
Mapping susceptible loci underlying atherosclerosis with the identification of BM-
derived cells playing an important role was the main focus in chapter 2. Fine mapping of 
the Athsq1 interval using subcongenic strains revealed a distal locus showing 
proatherogenic activity during early atherosclerosis development (6-wk WTD) and a 
proximal locus conferring accelerated atherosclerosis at a later timepoint (9-wk WTD). 
The identification of two susceptibility loci under one linkage peak is not-unusual. Typical 
linkage peaks are very large and contains hundreds of genes. For example, a locus 
affecting seizure susceptibility in mice composed of multiple loci each having small 
effects (4). Another example was the identification of Alox5 in the congenic interval (124) 




Thus, the mapping of disease susceptibility locus should be performed with caution as 
multiple alleles would either work together to increase the phenotype or cancel out 
opposing effects.  
Animal models are important tools for biomedical research because their 
environmental exposure can be easily controlled and manipulated. The finding of loci 
acting at different phases during disease development stresses the utility of mouse 
models to define the role of genes in disease etiology, as this can be examined by time 
course experiments with the characterization of specific markers or morphological 
features during different phases of the diseae. Similarly, mouse models enable us to 
define culprit cells types involved in the pathogenesis of the disease. For instance, 
reciprocal BM transplantation experiments revealed that BM-derived cells are 
responsible for the atherosclerotic phenotype observed in the 17-Mb congenics. Thus, 
mouse models facilitate our understanding of the pathophysiology underlying diseases. 
The panel of subcongenic strains enabled the refinement of the locus to a region 
that contains 8-21 genes including the region of homology with the highly replicated 
human CHD locus on chr9p21. The narrowing of the susceptibility locus in our congenic 
strain was based on the inclusion of pro-atherosclerotic 11-Mb interval and exclusion of 
the 4-Mb interval that does not have an effect on atherosclerosis. However, exclusion of 
the 4-Mb proximal tip as a causal candidate region alone does not rule out the possibility 
of a more complex genetic architecture. Epistasis, as defined by genetic interaction of 
the genotype at one locus that affects phenotypic expression determined by another 
locus, has been documented in several disease states (208-211). An example of 
synergism between loci has been demonstrated in a mouse model of systemic lupus 




systemic autoimmunity develops while each allele alone fails to confer severe 
autoimmunity (212). These data suggest that epistasis between two susceptibility alleles 
leads to a greater incidence in disease severity than individual loci. Therefore, the 4-Mb 
congenic might need in conjunction with some other distant locus/loci to confer the 
atherosclerosis phenotype. 
We have shown that the mice deficient in Cdkn2a (p16INK4a and p19ARF) results in 
increased atherosclerosis and is associated with increased proliferation of monocytes 
and expansion of Ly6Chi inflammatory subset. The proteins encoded from the Cdkn2a/b 
(p16INK4a, p19ARF and p15INK4b) locus are cell cycle inhibitors and have been investigated 
actively and intensively in the field of cancer. On the other hand, recent studies have 
shed light of understanding genes from this locus and its relationship to CHD (104, 166, 
167, 172). Perhaps atherosclerosis and cancer can be viewed as similar diseases 
having some common molecular pathways leading to disease development and 
progression. Macrophages play a key role in the pathogenesis of both atherosclerosis 
and cancer. In cancer, they are directly involved in tumor progression and metastasis 
(213). Macrophages are found at regions of basement-membrane breakdown during the 
transition from malignant to advanced tumors (213). The secretion of matrix 
metalloproteinases (MMPs) allows the invasion of tumor cells into the basement 
membrane (214). In atherosclerosis, vulnerable plaques and thrombosis have been 
linked to MMP secretion by macrophages. Thus, matrix remodeling is an example of a 
common pathway shared by both diseases. Decreased expression of p16INK4a in human 
lung cancer cell lines and glioma has been associated with increased MMP secretion 




and p19ARF) mice, it is possible that accelerated atherosclerosis phenotype observed in 
these mice might be due to increased MMP secretion. 
Progressive angiogenesis is another common process in cancer and 
atherosclerosis. Angiogenesis in human atherosclerotic lesions has been associated 
with plaque expansion and vulnerability, as a result plaque rupture and thrombosis 
occurs (217). Tumor angiogenesis is associated with several malignancies such as 
breast cancer and prostate cancer. New blood vessel formation promotes the transition 
from hyperplasia (cellular multiplication) to neoplasia (uncontrolled proliferative state) 
(218). Neovascularization also facilitates tumor cell extravasation (exit from vessels) and 
metastasis to other organs. Perhaps loss of function of p16NK4a or p19ARF in the 
hematopoietic cells modulating angiogenesis in cancer (219, 220) may be one pathway 
of promoting atherosclerotic plaque development. Angiogenesis is not a common feature 
of mouse atherosclerotic plaques but can be observed in long term cholesterol-fed mice 
(111). This would be a great model to test mice deficient in p16NK4a and p19ARF 
exacerbates atheromas via promoting angiogenesis.  
A number of genes involved in cell cycle regulation have been shown to play a role 
in atherosclerosis. Various cell cycle regulators, including transcriptional regulators p53 
(221-224), retinoblastoma (Rb) (225), and the Cip/Kip family members, p27 (226-229) 
and p21 (230, 231) have been assessed its role in atherosclerosis by using genetically- 
altered animal models. There are evidence suggest that p53 plays a role in 
atherosclerosis development. Guevara et al. (221) first reported that Apoe-null mice with 
global inactivation of p53 exhibit accelerated atheroma development in the aorta with 
increased cell proliferation. Subsequent studies demonstrated a role for hematopoietic 




not identified. Apoptosis was ruled out as a pathogenic mechanism in this model (224). 
Thus it is not clear whether p53 deficiency leads to atherosclerosis via proliferation or 
apoptosis. Inactivation of Rb in macrophages of Apoe-null mice leads to a 51% increase 
in atherosclerotic lesion area, with a 2.6 fold increase in lesional macrophage 
proliferation, compare to Apoe-null controls (225). p27 has been shown to be athero-
protective via inhibiting macrophage and SMC proliferation (227, 228). On the other 
hand, another cell cycle inhibitor, p21, hsa been shown to confer athero-protection (231) 
or atherosclerosis susceptibility (230) in various studies. Thus, our findings of increased 
atherosclerosis in Ldlr-null mice with haplo-insufficiency of p16NK4a and p19ARF is 
consistent with studies in the literature regarding a role for regulators of cell proliferation 
in atherogenesis.  
The plethora of genes/variants identified through GWASs has been fruitful. 
However, we are currently at the early stage of understanding the biological basis of 
these variants. Mouse models have been informative to understand genes identified by 
GWASs and its underlying mechanisms for metabolic syndromes (139, 166, 167, 172, 
181, 182), with the goal of their clinical usage in the near future. This project started with 
an unbiased approach (157, 162) to identify a locus on mouse chr 4 that confers 
susceptibility for atherosclerosis. The thesis further focused on a region that contains the 
region of homology with the human CHD locus on chr 9p21. Here, we provide a link 
between accelerated atherosclerosis, in which the mechanism of action is through the 
elevation of inflammatory monocytes. Complementing the well known risk factors such 
as plasma lipid levels and the establishment of C-reactive protein as an inflammatory 
marker, this will help propel us to an era in which the biology of atherosclerosis 









Many studies have revealed the importance of different monocyte subsets in 
association with CHD related complications (33-40, 159). Monocytosis has been shown 
to be an independent risk factor for CHD (33, 34). The CD14+CD16- subset has been 
shown to correlate with risk factors and family history in patients with stable CHD (35), 
levels of LDL and lipoprotein(a) (36) and correlate inversely to left ventricular recovery 
after MI (37). On the other hand, CD14+CD16+monocyte counts have been associated 
with uptake of oxLDL(38) and increased cardiovascular events (39, 40). Chronic kidney 
patients have an increased risk of CVD events, and this is associated with increased 
levels of CD14+CD16+ (159). There is no clear homolog of monocyte subsets between 
mouse and human (32). In our study, we have found increased proliferation of 
monocytes and levels of Ly6Chi subset with mice deficient in Cdkn2a. Given the clear 
role monocytosis plays in the development of atherosclerosis in the clinical setting, it 
remains important to determine if chr 9p21 risk allele carriers in humans have increases 
in specific monocyte subsets. In collaboration with Dr. Angali Ganda, we are trying to 
see whether 9p21 risk allele carriers with chronic kidney disease have increased levels 
of certain monocyte subsets. In addition, it would be interesting to see whether there is 
increased ex vivo proliferative activity of the human monocyte subsets.  
To test whether there is increased proliferative activity of monocyte/macrophages in 
atherosclerotic plaques derived from Cdkn2a-deficient mice, we examined lesions from a 
small cohort of B6-Ldlr-/-, Cdkn2a+/- mice compared to controls by examining BrdU 
incorporation within lesions using immunohistochemistry. While ample numbers of cells 
(mean = 42-47 cells) stained positively following a 7-day pulse, the within-group variation 
was high and power calculations indicated that we would need to study 50 mice/group to 




magnitude to the difference in lesion area (i.e. ~30%). Therefore in order to achieve a 
significant biological effect, we would use homozygous Cdkn2a-/- compared to Cdkn2a+/+ 
mice (on a B6-Ldlr-/- background) to examine the proliferative activity within the 
atherosclerotic lesions.   
In our study, we have found that deficiency of Cdkn2a leads to atherosclerosis via the 
action of BM-derived cells. To test this hypothesis that the expression levels of Cdkn2a 
in BM affects atherosclerosis development post-transplantionally in humans, it would be 
intriguing to see whether patients receiving BM transplantation have an increased risk of 
developing CHD dependent on donor genotype at the the 9p21 risk allele. To test the 
genotypic effect of the host’s environment to CHD development, including vascular wall 
cells of the recipient, hormonal effects of the host, it is possible to genotype the 
recipients for the 9p21 risk allele and see whether recipient with the risk allele is 
associated with exacerbated CHD development. 
Rheumatoid arthritis (RA) is associated with an increased risk for CVD events, such 
as MI and stroke (232). Developing rheumatoid arthritis is 50% attributable to genetic 
factors (233). Systemic inflammation has played a central role in driving the increased 
CHD risk in RA patients (233). Many risk alleles associated with RA has been identified 
by GWASs (234), with the associated SNPs located near genes with known immune 
function. Interestingly, many associations are located near genes that encode proteins 
that are important for T-cell function, activation and responsiveness (234). In our studies, 
we found an increased level of inflammatory monocyte subset in a mouse model 
simulating 9p21 risk allele carriers in humans. The expression levels of Cdkn2a in 
relationship to RA and CHD is not understood. To understand this relationship, this could 




retrospective or prospective study to see whether 9p21 risk allele carriers in RA patients 
have increased risk of developing CHD.  
 The 9p21 CHD risk locus is associated with abdominal and intracranial aneurysms 
(98) and ischemic stroke (202, 203). Aneurysmal diseases arise in the setting of 
atherosclerosis (235). The main histological feature of aneurysm is chronic medial 
degradation, which is mainly caused by proteases (matrix metalloproteinases, serine 
proteases and cysteine proteases) secreted by macrophages and SMCs (236). In 
ischemic stroke, macrophage accumulation has been associated with severity of brain 
injury (206) and that the deficiency of MCP-1 (monocyte chemoattractant protein-1) in 
mice leads to decreased cerebral aneurysm formation and macrophage accumulation. 
Thus, it would be interesting to examine whether Cdkn2a-/- mice have any morphological 
features of aneurysm and stroke in the vessel wall, including medial degradation and 
increased macrophage accumulation, and whether these mice secrete more proteases 
in the arterial wall.   
In this thesis, we have demonstrated a mechanistic link between decreased Cdkn2a 
expression, increased monocytes/macrophages proliferation with the expansion of an 
inflammatory monocyte subset and increased atherosclerosis. Together, these data 
illustrate the feasibility of mouse models as tools to elucidate causal gene(s)/loci and 
potential pathogenic mechanisms underlying genome-wide association studies-identified 
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